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Chronic kidney disease (CKD) is a progressive disease that
represents a public health problem in our modern society
affecting 5-7% of the world’s population. Recent clinical
studies have described that CKD is an independent risk
factor for cardiovascular disease. CKD patients have a 10 to
100 times higher risk than healthy people of developing
cardiovascular diseases, including hypertension, diabetes,
and hyperlipidemias, all of them associated with high mor-
bidity and mortality. CKD is characterized by a progressive
destruction of the renal parenchyma, sustained inflamma-
tion, and a functionality loss of the nephron that leads to
end-stage renal disease (ESRD). The dysfunction of the
nephron triggers cellular and molecular processes that seek
to promote the compensatory growth of the nephron. In
certain cases, this compensatory mechanism becomes patho-
logical, contributing to renal damage progression leading to
ESRD. Nowadays, one of the biggest problems in nephrology
is the increased number of patients who progress up to
ESRD. These patients require, in 100% of cases, renal replace-
ment therapy such as dialysis (hemodialysis or peritoneal
dialysis) or kidney transplantation. Importantly, 50% of
patients who undergo dialysis, cannot stand more than three
years with these replacement therapies, hence the importance
of developing new strategies that could restore kidney func-
tion or, at least, delay disease progression.
This special issue contains 6 papers, including original
research articles, clinical research articles, and a review, rang-
ing from detailed studies of the key molecular mechanism
associated to inflammation and fibrosis in renal diseases.
In the clinical field, there is a need for more studies that
can deepen in the identification of new biomarkers for early
detection and prevention of kidney disease progression.
The manuscript entitled “Circulating CD14+CD163+CD206+
M2 Monocytes Are Increased in Patients with Early Stage of
Idiopathic Membranous Nephropathy” by J. Hou et al.
studied the changes in peripheral blood monocytes and their
clinical significance in patients with an early stage of idio-
pathic membranous nephropathy (IMN). Approximately
30–40% of patients with this common type of nephrotic
syndrome progress to CKD. Recent studies have shown the
importance of the differentiation of macrophages in the
pathogenesis of chronic inflammatory process, including
CKD. Monocytes are the progenitors of dendritic cells or
macrophages in the tissues. The ratio of M1/M2 monocytes/
macrophages is known to be modified in several kidney
diseases but this has not been studied in detail for IMN.
M1 monocytes release proinflammatory cytokines such as
IL-12 (Th1 immune response), while M2 monocytes secrete
anti-inflammatory mediators such as IL-10 (Th2 immune
response) and have been suggested to exert profibrotic
actions. In this manuscript, the authors show that CD14
+CD163+CD206+ M2 monocytes are relevant for the path-
ological process in incipient disease and are correlated with
the severity of the disease. The authors also propose that
IL-10+ M2 cells should be a useful marker for evaluating
the severity of incipient IMN. Cell-based therapy related
to M2 macrophages is an active field of research. The
phenotype and function of macrophages at the different
CKD stages are not well defined yet, since injection of dif-
ferent types of macrophages (bone marrow-derived,
splenocyte-derived, or cell line-derived macrophages) in
different models of experimental renal damage has revealed
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opposite results. Therefore, future studies are needed to
define possible macrophage-based therapies.
The study by A. Żyłka et al. entitled “Markers of Glomer-
ular and Tubular Damage in the Early Stage of Kidney
Disease in Type 2 Diabetic Patients” analyzed several
markers of glomerular and tubular damage in patients
with type 2 diabetes with these inclusion parameters:
eGFR > 60ml/min/1.73m2 and uACR < 300mg/g, and at
different stages of CKD (G1/G2, A1/A2). In this study, the
authors identified serum cystatin C and urine IgG, transfer-
rin, and NGAL as the best indicators of glomerular damage,
whereas urine NGAL, KIM-1, or uromodulin could be indi-
cators of tubular damage. The urinary markers are associated
with increase of albuminuria, while both serum and urine
NGAL were significantly associated with eGFR decline.
Although these findings still need to be confirmed in a large
number of patients, these data indicates that combination
of biomarkers in serum and urine could be useful for the
clinical management of diabetic patients.
Cardiovascular and heart damage is the most frequent
consequence of CKD. Serum levels of sST2 (soluble sup-
pression of tumorigenicity 2), a novel biomarker of fibro-
sis and cardiac remodeling in heart failure patients, are
independent of eGFR and age. Previous studies described
that the BCN Bio-HF score, an algorithm derived from
a real-life cohort, based on soluble ST2 in addition to
other predictive serum biomarkers (NT-proBNP and
hs-cTnT) and clinical variables/treatments (beta-blockers
ARBs/ACEI, statins, and furosemide), could be a useful
tool in CV risk stratification of nondialyzed CKD patients.
M. Plawecki et al. in their manuscript entitled “sST2 as a
New Biomarker of Chronic Kidney Disease-Induced Car-
diac Remodeling: Impact on Risk Prediction” evaluate
the predictive potential of serum sST2 in CKD patients
and show that serum sST2 alone is not a good predictive
biomarker of major adverse coronary events or death in
CKD patients.
Y. Xu et al. in their manuscript entitled “Apoptosis-
Associated Speck-Like Protein Containing a CARD Deletion
Ameliorates Unilateral Ureteral Obstruction Induced Renal
Fibrosis and Endoplasmic Reticulum Stress in Mice” showed
the key role of the apoptosis-associated speck-like protein
containing a CARD (ASC), a component of the inflamma-
some, in the progression of interstitial fibrosis in a model of
experimental renal damage. The genetic deletion of ASC in
mice submitted to unilateral ureter obstruction significantly
reduced the inflammatory cell infiltration in the kidney.
The ASC knockout mice showed a diminution in apoptosis
(lower number of TUNEL-positive cells, decreased levels of
Bax and caspase 3, and increased levels of Bcl-2) and in
fibrosis assessed by the expression of ECM proteins, such as
fibronectin and collagen I. Additionally, they demonstrated
improvement of endoplasmic reticulum stress as evidenced
by the reduced BIP, p-eIF2α/eIF2α, ATF4, and CHOP pro-
tein levels in the obstructed ASC-deleted mice compared to
obstructedWTmice. These results demonstrated the key role
of the ASC inflammasome component in the regulation of
the inflammatory and fibrotic processes in experimental
renal damage.
Another study submitted to this special issue by K.
Ramani et al. is entitled “IL-17 Receptor Signaling Negatively
Regulates the Development of Tubulointerstitial Fibrosis in
the Kidney.” In this study, the authors showed the crucial role
of the IL-17A signaling pathway in the modulation of renal
fibrosis induced by comparing fibrosis upon ureteral obstruc-
tion in the Il17ra genetic deleted as compared to wild-type
mice. Interestingly, this study demonstrated the novel rela-
tionship between the antifibrotic kallikrein-kinin system
(KKS) and the IL-17A signaling pathway in the kidney. Inter-
estingly, they found that treatment of the more fibrosis-prone
Il17ra-/- mice with bradykinin, the major end-product of
KKS activation, confers protection against fibrosis by upreg-
ulating the expression of matrix degrading enzymes such as
the metalloproteinase MMP2. Moreover, the group identified
the bradykinin receptors Bdkrb2 and Bdkrb1 as downstream
mediators of IL-17-KKS-axis and administration of a brady-
kinin receptor 1 or 2 agonist in vivo showed a clear diminu-
tion of renal fibrosis.
Finally, the review article from S. Rayego-Mateos et al.
entitled “Role of Epidermal Growth Factor Receptor (EGFR)
and Its Ligands in Kidney Inflammation and Damage”
describes the key role of the EGFR signaling pathway in the
pathogenesis of inflammatory renal damage, with special
attention to the role of some EGFR ligands in this process
such as TGF-A and HBEGF that play a crucial role in EGFR
transactivation through the modulation of key factors of
renal damage and inflammation such as Ang II, aldosterone,
and TWEAK. The authors specially analyzed the role of
CTGF/CCN2, one recently described EGFR ligand with a
strong impact in inflammatory and profibrotic processes in
kidney disease.
In summary, this special issue will help to understand the
inflammatory and profibrotic mechanisms that regulate key
processes in the renal pathology and the new therapeutic
strategies that are developed for the treatment and preven-
tion of CKD.
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